“For drugs against PD-1/PD-L1 to be effective ... clones to the same type of tumour tissue can produce different staining patterns. “Non-specificity can be a big problem,” he says.

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch ...